Pneumocystis pneumonia associated with human immunodeficiency virus

Clin Chest Med. 2013 Jun;34(2):229-41. doi: 10.1016/j.ccm.2013.02.001. Epub 2013 Apr 8.

Abstract

Pneumocystis pneumonia (PCP) is caused by the yeastlike fungus Pneumocystis. Despite the widespread availability of specific anti-Pneumocystis prophylaxis and of combination antiretroviral therapy (ART), PCP remains a common AIDS-defining presentation. PCP is increasingly recognized among persons living in Africa. Pneumocystis cannot be cultured and bronchoalveolar lavage is the gold standard diagnostic test to diagnose PCP. Use of adjunctive biomarkers for diagnosis requires further evaluation. Trimethoprim-sulfamethoxazole remains the preferred first-line treatment regimen. In the era of ART, mortality from PCP is approximately 10% to 12%. The optimal time to start ART in a patient with PCP remains uncertain.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections* / diagnosis
  • AIDS-Related Opportunistic Infections* / drug therapy
  • Africa
  • Anti-Retroviral Agents / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Biomarkers / blood
  • Bronchoalveolar Lavage
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • Humans
  • Pneumocystis / isolation & purification
  • Pneumonia, Pneumocystis* / diagnosis
  • Pneumonia, Pneumocystis* / drug therapy

Substances

  • Anti-Retroviral Agents
  • Antifungal Agents
  • Biomarkers